Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.55 USD | -3.14% | +0.94% | +11.70% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.70% | 484M | |
+34.25% | 50.85B | |
+0.73% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.95% | 26.11B | |
-21.60% | 19.13B | |
+9.52% | 13.05B | |
+27.09% | 12.16B | |
+24.06% | 12.08B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Sector Update: Health Care